Ocular side effects of bisphosphonates: A case report and literature review

Canadian Family Physician

Volumn 56, Issue 10, 2010, Pages 1015-1017

  McKague, Meredith ^a,b   Jorgenson, Derek ^c   Buxton, Kelly A ^c  

^a West Winds Primary Health Centre ^*

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIHISTAMINIC AGENT; DEXAMETHASONE; ERYTHROMYCIN; ETIDRONIC ACID; RISEDRONIC ACID; TOBRAMYCIN;

AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BONE DENSITOMETRY; CASE REPORT; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; GENERAL PRACTITIONER; HUMAN; OSTEOPOROSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CONJUNCTIVITIS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 78049428909     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, et al. Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can 2006;28(2 Suppl 1):S95-112.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23(4):570-8.
3. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23(4):508-16.
4. Khan A. Bisphosphonate-associated osteonecrosis of the jaw. Can Fam Physician 2008;54:1019-21.
5. Moore MM, Beith JM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust 2008;188(6):370-1.
6. Springuel P, McMorran M. Bisphosphonates and ocular disorders. Can Adverse Drug React Newsl 2003;13(4):1-2. Available from: www.hc-sc.gc.ca/dhp- mps/alt-formats/hpfb-dgpsa/pdf/medeff/carn-bcei-v13n4-eng.pdf. Accessed 2010 Aug 25.
7. Aurich-Barrera B, Wilton L, Harris S, Shakir S. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Saf 2006;29(2):151-60. (Pubitemid 43213888)
8. Adverse Drug Reactions Advisory Committee. Bisphosphonates and ocular inflammation. Aust Adverse Drug React Bull 2004;23(2):7-8. Available from: www.tga.gov.au/adr/aadrb/aadr0404.htm#a3. Accessed 2010 Aug 25.
9. Kiuru AK, Fraunfelder FW, Edwards IR. Bisphosphonates and ocular side effects [poster]. Uppsala, Sweden: Uppsala Monitoring Centre and WHO Collaborating Centre for International Drug Monitoring; 2004. Available from: www.who-umc.org/graphics/6999.pdf. Accessed 2010 Aug 25.
10. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111(7):1275-9.
11. French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008;28(6):889-93.
12. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003;348(12):1187-8.
13. Fraunfelder FW. Ocular side effects associated with bisphosphonates. Drugs Today (Barc) 2003;39(11):829-35.
14. Banal F, Briot K, Ayoub G, Dougados M, Roux C. Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol 2008;35(12):2458-9.
15. Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (Lond) 2005;19(2):221-2.
16. Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol) 2006;18(7):545-6.
17. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135(2):219-22.
18. Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999;117(6):837-8.
19. Wirbelauer C. Management of the red eye for the primary care physician. Am J Med 2006;119(4):302-6.
20. Bal SK, Hollingworth GR. Red eye. BMJ 2005;331(7514):438.